Global Mice Model Market Size Industry Analysis, Pricing and Opportunities by Region with Competitive Landscape Forecast 2032

Mice Model Market Dynamics:

Rising investments in biomedical research and drug discovery are driving the market growth

The increasing investment in biomedical research, pharmaceutical development, and preclinical drug discovery is a key factor driving the growth of the global Mice Model market. Mice models remain the gold standard for studying disease mechanisms, evaluating drug efficacy and safety, and advancing translational research due to their genetic similarity to humans. Growing research activities in oncology, immunology, neuroscience, cardiovascular diseases, and rare genetic disorders are accelerating the demand for transgenic, knockout, knock-in, and humanized mouse models. Furthermore, rising funding from governments, academic institutions, and private organizations for life sciences research and precision medicine is supporting the widespread adoption of advanced mice models across research laboratories and pharmaceutical companies.

High development costs and ethical concerns regarding animal testing are restraining the market growth

The high costs associated with developing, breeding, and maintaining genetically engineered mice models pose a significant challenge to market growth. Advanced technologies such as CRISPR-based gene editing, specialized breeding programs, and pathogen-free facilities require substantial investments, increasing the overall cost of research. Additionally, growing ethical concerns related to animal experimentation and stringent regulations governing the use of laboratory animals have encouraged researchers to adopt alternative testing methods, including organ-on-chip technologies, 3D cell cultures, and computational models, which may limit market expansion in certain research areas.

Advancements in gene-editing technologies and personalized medicine are creating growth opportunities for the market

Continuous advancements in gene-editing technologies such as CRISPR-Cas9, TALENs, and other genome engineering platforms are creating significant growth opportunities for the Mice Model market. These technologies enable the rapid development of highly accurate disease-specific and humanized mouse models that improve the efficiency of drug discovery and precision medicine research. Moreover, the increasing focus on personalized therapies, regenerative medicine, cell and gene therapy, and rare disease research is driving demand for customized mouse models. Expanding collaborations between biotechnology companies, pharmaceutical manufacturers, contract research organizations (CROs), and academic institutions are further accelerating innovation and market growth.

Availability of alternative preclinical models and regulatory complexities are challenging the market growth

The growing adoption of alternative preclinical research models, including organoids, organ-on-chip platforms, in vitro cell-based assays, and artificial intelligence-driven drug discovery, is posing a challenge to the traditional Mice Model market. These alternatives offer faster, cost-effective, and ethically acceptable approaches for early-stage drug screening and disease modeling. In addition, evolving regulatory requirements related to animal welfare, experimental protocols, and research compliance increase the complexity and cost of conducting animal studies. Balancing scientific accuracy, regulatory compliance, and ethical considerations remains a significant challenge for market participants throughout the forecast period.

Key Statistics: Global Cancer Incidence Driving Oncology Mouse Model Adoption

Global Mice Model Market Segment Analysis:

By Model Type,

The Genetically Engineered Mice segment is expected to dominate the global Mice Model market during the 2025–2032 forecast period owing to the increasing adoption of transgenic, knockout, knock-in, and humanized mouse models in drug discovery, oncology, immunology, neuroscience, and rare disease research. The widespread use of gene-editing technologies such as CRISPR-Cas9 has significantly improved the efficiency of developing disease-specific models, accelerating pharmaceutical and biotechnology research. Inbred Mice continue to account for a substantial market share due to their genetic uniformity, reproducibility, and extensive use in biomedical research and preclinical studies, making them a preferred choice for laboratory experiments and therapeutic evaluations.

Meanwhile, the Outbred Mice segment is expected to witness steady growth as researchers increasingly utilize genetically diverse populations to better replicate human biological variability, particularly in toxicology, pharmacology, and infectious disease studies. Hybrid/Congenic Mice are also gaining traction due to their ability to combine desirable genetic characteristics for specialized disease modeling and immunological research. Growing investments in precision medicine, personalized therapeutics, and translational research are expected to support the continued adoption of all model types, enabling researchers to address increasingly complex biomedical challenges.

By Technology,

The CRISPR segment is expected to dominate the Mice Model market throughout the forecast period due to its exceptional precision, speed, and cost-effectiveness in genome editing. The technology has revolutionized the development of transgenic and humanized mouse models by enabling targeted gene modifications for cancer research, genetic disorders, immunology, and regenerative medicine. Increasing investments in precision medicine, gene therapy, and personalized healthcare continue to accelerate the adoption of CRISPR-based mouse model development. Embryonic Stem Cell Injection technology also maintains a significant market share due to its well-established role in generating knockout and knock-in mouse models for complex genetic research and pharmaceutical development.

The Microinjection segment continues to witness stable demand as it remains a widely adopted technique for introducing genetic material into fertilized embryos, particularly in transgenic animal production and developmental biology research. Nuclear Transfer technology is expected to experience moderate growth owing to its applications in cloning, disease modeling, and regenerative medicine, although its adoption remains limited by technical complexity and high costs. Additionally, Other Technologies, including emerging genome engineering and reproductive technologies, are gaining attention as research institutions and biotechnology companies continue to explore innovative methods for improving model development efficiency, accuracy, and scalability. Together, these technological advancements are driving the evolution of next-generation mice models for preclinical and translational research.

Competitive Landscape for Global Mice Model  Market

The global Mice Model market is highly competitive and innovation-driven, with biotechnology companies, laboratory animal suppliers, contract research organizations (CROs), and preclinical research service providers focusing on the development of genetically engineered, humanized, and disease-specific mouse models. Companies are making substantial investments in CRISPR-based genome editing, transgenic technologies, breeding capabilities, and advanced phenotyping platforms to accelerate drug discovery and translational research. Strategic initiatives such as mergers and acquisitions, licensing agreements, research collaborations, and expansion of breeding and manufacturing facilities are enabling market participants to strengthen their product portfolios and global presence. The growing demand for precision medicine, oncology research, immunotherapy development, and rare disease modeling continues to intensify competition across the market.

Leading companies are also emphasizing automation, digital colony management, high-throughput phenotyping, and customized mouse model development to meet the evolving requirements of pharmaceutical companies, biotechnology firms, and academic research institutes. Additionally, vendors are expanding their portfolios of humanized and immunodeficient mouse models while enhancing contract research services to support preclinical testing and regulatory studies. Key players operating in the global Mice Model market include The Jackson Laboratory (JAX), Charles River Laboratories International, Inc., Taconic Biosciences, Inc., genOway S.A., Janvier Labs, Envigo (Inotiv Inc.), Harbour BioMed, Trans Genic Inc., Cyagen Biosciences Inc., and Crown Bioscience, all of which continue to strengthen their market positions through technological innovation, strategic collaborations, portfolio expansion, and global distribution networks.

Mice Model Industry Ecosystem:-

Mice Model Market Scope: Inquire before buying

Mice Model Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (razil, Argentina Rest of South America)

Global Mice Model Market, Key Players:

Global Mice Model Providers in North America:
1. Laboratory Corporation of America Holdings (Burlington, North Carolina, USA)
2. Charles River Laboratories International, Inc. (Wilmington, Massachusetts, USA)
3. The Jackson Laboratory (Bar Harbor, Maine, USA)
4. Taconic Biosciences, Inc. (Germantown, New York, USA)
5. Crown Biosciences (San Diego, California, USA)
6. TransCure bioServices (Montreal, Quebec, Canada)
7. Cyagen Biosciences (Canton, Massachusetts, USA)
8. The Andersons, Inc. (Maumee, Ohio, USA)
9. Allentown, LLC (Allentown, New Jersey, USA))
Global Mice Model Providers in Europe:
10. Envigo (Huntingdon, Cambridgeshire, UK) [Previously known as Harlan Laboratories]
11. Janvier Labs (Yvonné, France)
12. Genoway (Lyon, France)
13. Ingenious Targeting Laboratory (Ghent, Belgium)
Global Mice Model Providers in Asia-Pacific:
14. Trans Genic, Inc. (Fukuoka, Japan)
15. Harbour Antibodies Bv (Harbin, China) [Harbour Biomed subsidiary]
16. PolyGene (Beijing, China)
17. GVK BIO (Hyderabad, India)
18. Ozgene Pty Ltd. (Brisbane, Queensland, Australia)

FAQs:
2. Which region has the largest share in Global Mice Model Market?
Ans: North America region holds the highest share in 2025.

1. What was the Global Mice Model Market size in 2025?
Ans: The Global Mice Model Market size was USD 1.71 Billion in 2025.

3. What segments are covered in Global Mice Model market?
Ans: Global Mice Model Market is segmented into Model Type, Technology, Application, End-User and region.

4. Who are the key players in Global Mice Model market?
Ans: The important key players in the Global Mice Model Market are – Laboratory Corporation of America Holdings (Burlington, North Carolina, USA), Charles River Laboratories International, Inc. (Wilmington, Massachusetts, USA), The Jackson Laboratory (Bar Harbor, Maine, USA), Taconic Biosciences, Inc. (Germantown, New York, USA), Crown Biosciences (San Diego, California, USA), TransCure bioServices (Montreal, Quebec, Canada), Cyagen Biosciences (Canton, Massachusetts, USA), The Andersons, Inc. (Maumee, Ohio, USA),Allentown, LLC (Allentown, New Jersey, USA)and Others.